目的 探讨术前静注艾司氯胺酮在腹腔镜结直肠癌根治术患者中的应用效果。方法 前瞻性分析2024年1月—2025年4月在厦门市中医院行腹腔镜结直肠癌根治术患者的临床资料，根据随机数字表法将患者分为两组：对照组40例，术前5 min予5 mL生理盐水；观察组40例，术前5 min予以0.25 mg/kg艾司氯胺酮（以生理盐水配置成5 mL）。比较围术期指标、炎症因子、负性情绪、疼痛情况、不良反应。结果 观察组的手术时间、麻醉时间、术中出血量分别为（213.54±64.22）min、（240.67±81.26）min、（141.31±45.03）mL，与对照组的（210.43±65.71）min、（244.25±81.33）min、（137.64±42.75）mL比较，差异均无统计学意义（t=0.214、0.197、0.374，P均＞0.05），而观察组丙泊酚、瑞芬太尼用量分别为（1 075.52±134.37）mg、（1 267.18±242.26）μg，虽然低于对照组的（1?126.64±150.21）mg、（1 352.50±295.14）μg，但差异也无统计学意义（t=1.604、1.413，P均＞0.05）；观察组在术后24 h的肿瘤坏死因子-α、白介素-6、C反应蛋白水平分别为（54.52±9.64）pg/mL、（40.08±7.75）pg/mL、（30.38±6.93）mg/L，均低于对照组的（77.31±10.86）pg/mL、（56.35±9.47）pg/mL、（43.73±7.61）mg/L（t=9.926、8.409、8.203，P均＜0.05）；术后1 d的焦虑、抑郁自评量表评分及术后1 h、6 h、12 h、24 h咳嗽时的疼痛视觉模拟量表评分分别为（51.92±4.41）分、（53.96±4.47）分、（3.59±1.14）分、（3.06±1.01）分、（2.89±0.91）分、（2.57±0.76）分，均低于对照组的（55.06±5.12）分、（57.21±5.19）分、（4.27±1.36）分、（3.68±1.18）分、（3.41±1.06）分、（2.96±0.92）分（t=2.939、3.001、2.423、2.525、2.329、2.067，P均＜0.05），但两组术后48 h咳嗽时疼痛视觉模拟量表评分比较差异无统计学意义（P＞0.05）；两组术后不良反应发生率也无显著差异（P＜0.05）。结论 在腹腔镜结直肠癌根治术术前静注艾司氯胺酮可有效降低术后炎症反应水平，减轻术后疼痛，缓解术后负性情绪，且不会增加患者术后不良反应发生率。
Objective To explore the application effect of preoperative intravenous injection of esketamine in patients undergoing laproscopic radical resection of colorectal cancer．Methods The clinical data of patient who underwent laparoscopic radical resection of colorectal cancer in Xiamen Hospital of Traditional Chinese Medicine from January 2024 to April 2025 were retrospectively analyzed．The patients were divided into two groups according to the random number table method：40 cases in the control group were given 5 mL saline，five minutes before operation，40 cases in the observation group were treated with 0.25 mg / kg esketamine（in 5 mL saline）five minutes before operation．The perioperative indicators，inflammatory factors，negative emotions，pain and adverse reactions were compared between two groups．Results The operation time，anesthesia time and intraoperative blood loss of the observation group were（213.54±64.22）min，（240.67±81.26）min and（141.31±45.03）mL，respectively，which were not significantly different from those of the control group（210.43±65.71）min，（244.25±81.33）min and（137.64±42.75）mL（t=0.214，0.197，0.374，all P＞0.05）．The dosage of propofol and remifentanil in the observation group were（1 075.52±134.37）mg and（1 267.18±242.26）μg，respectively，which were lower than those in the control group of （1126.64±150.21）mg and（1352.50±295.14）μg，but the difference was not statistically significant（t=1.604，1.413，P＞0.05）．The levels of tumor necrosis factor-α，interleukin-6 and C-reactive protein in the observation group at 24 h after operation were（54.52±9.64）pg / mL，（40.08±7.75）pg / mL and（30.38±6.93）mg / L，respectively，which were lower than those in the control group of （77.31±10.86）pg / ml，（56.35±9.47）pg / mL and 43.73±7.61）mg / L（t=9.926，8.409，8.203，all P＜0.05）．The scores of Anxiety and Depression Self-Rating Scale at 1 day after operation and the scores of pain visual analogue scale at 1 h，6 h，12 h and 24 h after operation were（51.92±4.41），（53.96±4.47），（3.59±1.14），（3.06±1.01），（2.89±0.91） and（2.57±0.76），respectively，which were lower than those of the control group（55.06±5.12），（57.21±5.19），（4.27±1.36），（3.68±1.18），（3.41±1.06） and（2.96±0.92）（t=2.939，3.001，2.423，2.525，2.329，2.067，P＜0.05）．However，no significant difference was observed in cough-related VAS scores between the groups at 48 h postoperatively（P＞0.05）．Adverse event rates showed no significance in two groups（P＞0.05）．Conclusions Preoperative administration of esketamine in laparoscopic colorectal cancer surgery can attenuate postoperative inflammation，decrease pain，mitigate negative emotions，without increasing the incidence of postoperative adverse reactions．
目的 探讨基于围手术期的口服营养补充（ONS）管理方案对胃癌手术患者的影响。方法 选取2020.1-2025.12本院收治的80例胃癌手术患者，分为观察组和对照组，每组40例。对照组实施围手术期常规膳食指导及肠外营养支持，观察组在对照组基础上实施规范化口服营养补充管理，比较相关指标。结果 术后7d，观察组总蛋白、白蛋白、前白蛋白水平均高于对照组（P<0.001）；观察组术后CRP及IL-6水平低于对照组（P<0.001）。观察组术后首次排气时间及住院天数短于对照组（P<0.001）；观察组术后并发症总发生率为7.50%，显著低于对照组的25.00%（P<0.05）。结论 胃癌围手术期实施口服营养补充管理，对营养状况的改善，炎症反应的减轻，胃肠功能的恢复，住院时间的缩短，降低并发症风险。
目的 探讨基于围手术期的口服营养补充（ONS）管理方案对胃癌手术患者的影响。方法 选取2020.1-2025.12本院收治的80例胃癌手术患者，分为观察组和对照组，每组40例。对照组实施围手术期常规膳食指导及肠外营养支持，观察组在对照组基础上实施规范化口服营养补充管理，比较相关指标。结果 术后7d，观察组总蛋白、白蛋白、前白蛋白水平均高于对照组（P<0.001）；观察组术后CRP及IL-6水平低于对照组（P<0.001）。观察组术后首次排气时间及住院天数短于对照组（P<0.001）；观察组术后并发症总发生率为7.50%，显著低于对照组的25.00%（P<0.05）。结论 胃癌围手术期实施口服营养补充管理，对营养状况的改善，炎症反应的减轻，胃肠功能的恢复，住院时间的缩短，降低并发症风险。
目的 探讨基于围手术期的口服营养补充（ONS）管理方案对胃癌手术患者的影响。方法 选取2020.1-2025.12本院收治的80例胃癌手术患者，分为观察组和对照组，每组40例。对照组实施围手术期常规膳食指导及肠外营养支持，观察组在对照组基础上实施规范化口服营养补充管理，比较相关指标。结果 术后7d，观察组总蛋白、白蛋白、前白蛋白水平均高于对照组（P<0.001）；观察组术后CRP及IL-6水平低于对照组（P<0.001）。观察组术后首次排气时间及住院天数短于对照组（P<0.001）；观察组术后并发症总发生率为7.50%，显著低于对照组的25.00%（P<0.05）。结论 胃癌围手术期实施口服营养补充管理，对营养状况的改善，炎症反应的减轻，胃肠功能的恢复，住院时间的缩短，降低并发症风险。
目的 观察桂枝加芍药汤个体化干预治疗儿童功能性腹痛的临床疗效。方法 选取2023年100名在广东省妇幼保健院门急诊就诊确诊为儿童功能性腹痛患儿。100名儿童随机分为两组，益生菌组50名、益生菌+中药个体化干预组50名。连续治疗1周。记录两组患儿卧立位心率、卧立位血压、Rutter 儿童行为量表和中医临床症状的改善情况。结果 益生菌+中药个体化干预组患儿治疗后卧立位心率和Rutter儿童行为量表中N行为评分比益生菌组下降，中医临床症状评分的有效率优于益生菌组。结论 桂枝加芍药汤个性化干预治疗儿童功能性腹痛疗效显著。
Objective To observe the clinical efficacy of individualized intervention with Guizhi plus Shaoyao Decoction in children with functional abdominal pain disorders（FAPDs）．Methods A total of 100 children diagnosed with FAPDs at the outpatient and emergency departments of Guangdong Women and Children Hospital were selected．These children were randomly divided into two groups：the probiotics group（50 cases）and the probiotics+traditional Chinese medicine individualized intervention group（50 cases）．Both groups received continuous treatment for 1 week．Parameters including supine/upright heart rates，supine/upright blood pressure，Rutter Children’s Behavior Questionnaire，and improvements in traditional Chinese clinical symptom scores were recorded．Results The probiotics+traditional Chinese medicine individualized intervention group exhibited significantly greater reductions in supine/upright heart rates and N-behavior scores compared to the probiotics group．The effective rate of Chinese clinical symptom scores was also significantly higher in the individualized intervention group．Conclusions Individualized intervention of Guizhi plus Shaoyao Decoction has a remarkable efficacy in treating FAPDs in children．
目的 探究经鼻间歇正压通气（NIPPV）和经鼻持续正压通气（NCPAP）作为早产儿呼吸窘迫综合征气管插管机械通气拔管后无创呼吸支持过渡的临床效果的差异。方法 纳入2021年1月—2023年6月在广东省吴川市妇幼保健计划生育服务中心治疗的新生儿呼吸窘迫综合征早产儿66例,用随机数字表法将患儿分为NIPPV组（33例）和NCPAP组（33例）。NIPPV组患儿予经鼻间歇正压通气作为过渡期无创呼吸支持,NCPAP组患儿则予以经鼻持续正压通气作为过渡期无创呼吸支持。对比两组患儿治疗前后血气分析结果、脱机失败率、无创呼吸支持时间、无创后吸氧时间、总给氧时间等指标。结果 接受无创呼吸支持12 h后,NIPPV组患儿的PaO2升至（76.46±1.10）mmHg,高于NCPAP组患儿的（75.51±2.15）mmHg（t=2.249,P=0.028）。此外,NIPPV组患儿的SaO2升至（96.36±0.52）%,也高于NCPAP组患儿的（96.07±0.59）%（t=2.138,P=0.034）。而NIPPV组患儿的PaCO2则降至（41.39±0.74）mmHg,较NCPAP组患儿的（41.87±0.95 ）mmHg低（t=-2.230,P=0.025）。NIPPV组无创呼吸支持时间为（3.09±0.52）d,短于NCPAP组的（3.45±0.62）d,且该差异有统计学意义（t=2.584,P=0.012）。同样的,NIPPV组总给氧时间（9.52±0.76）天较NCPAP组的（10.00±0.79）天短,且该差异有统计学意义（t=-2.548,P=0.013）。而两组在脱机失败率、无创呼吸支持后吸氧时间、不良反应发生率等方面比较差异无统计学意义（均P>0.05）。结论 与NCPAP模式相比,早产儿拔管后应用NIPPV模式进行无创呼吸支持取得的临床效果更优。
Objective To explore the difference of clinical effect of nasal intermittent positive pressure ventilation（NIPPV）and nasal continuous positive pressure ventilation（NCPAP）as non-invasive respiratory support mode after extubation in preterm infants with endotracheal intubation．Methods Sixty-six cases of preterm infants with neonatal respiratory distress syndrome treated in our hospital from January 2021 to June 2023 were included．All the subjects were randomly divided into NIPPV group（n=33）and NCPAP group（n=33）．The blood gas analysis results,weaning failure rate,non-invasive respiratory support time,oxygen inhalation time after noninvasive ventilation,total oxygen administration time．were compared between the two groups．Results After 12 hours of noninvasive respiratory support,PaO2 in the NIPPV group increased to（76.46±1.10）mmHg,which was significantly higher than that（75.51±2.15）mmHg in the NCPAP group（t=2.249,P=0.028）．In addition,SaO2 in the NIPPV group increased to （96.36±0.52）%,which was also significantly higher than that（96.07±0.59）% in the NCPAP group（t=2.138,P=0.034）．The PaCO2 in the NIPPV group decreased to （41.39±0.74）mmHg,which was lower than that（41.87±0.95）mmHg in the NCPAP group（t=-2.230,P=0.025）．The duration of non-invasive respiratory support in the NIPPV group（3.09±0.52） days was shorter than that（3.45±0.62）days in the NCPAP group,and the difference was statistically significant（t=2.584,P=0.012）．Similarly,the total duration of oxygen administration in the NIPPV group（9.52±0.76）days was shorter than that（10.00±0.79）days in the NCPAP group,and the difference was statistically significant（t=-2.548,P=0.013）．There were no significant differences in weaning failure rate,oxygen inhalation time after noninvasive respiratory support,and incidence of adverse reactions between the two groups（P>0.05）．Conclusions Compared with NCPAP mode,NIPPV mode for non-invasive respiratory support in preterm infants after extubating has better clinical effect,and it is worthy of clinical application．
目的 分析阿莫西林克拉维酸钾与第三代头孢类抗菌药联合应用于新生儿肺炎患儿的应用效果及其对患儿肠道菌群的影响。方法 选择在2021年2月—2022年11月期间于我院新生儿科接受相关治疗的100例新生儿肺炎患儿,依照简单随机化法将患儿分为研究组（n=50）及参照组（n=50）。给予参照组常规新生儿肺炎治疗,在此基础上给予研究组患者阿莫西林克拉维酸钾与第三代头孢类抗菌药的联合治疗。治疗结束后对比两组患儿的血清因子水平、肠道菌落情况、临床疗效以及不良反应发生情况。结果 治疗前,两组患儿的血清因子水平、肠道内菌群数量比较差异无统计学意义（P>0.05）,治疗后两组患儿的降钙素原（procalcitonin,PCT）、C-反应蛋白（C-reactive protein,CRP）、白细胞计数（white blood cell count,WBC）、肠球菌、肠杆菌、双歧杆菌以及乳酸杆菌水平均有改善（P<0.05）,其中研究组的PCT、CRP、WBC、肠球菌、双歧杆菌以及乳酸杆菌数量低于参照组,而研究组的肠杆菌数量高于参照组;同时研究组的临床有效率（94.00%）与参照组的临床有效率（86.00%）比较差异无统计学意义（P>0.05）;两组患儿的不良反应发生率比较差异无统计学意义（P>0.05）,但其中研究组腹泻的发生率高于参照组（P<0.05）。结论 在对新生儿肺炎患儿进行治疗时采取阿莫西林克拉维酸钾单纯治疗与阿莫西林克拉维酸钾+第三代头孢类抗菌药（头孢他啶）的临床疗效相当,联合用药虽能更为显著地减少患儿机体的细菌数量,改善血清因子水平,但更易发生腹泻的并发症,且为了减少耐药性,应适当采用单独用药。
Objective To analyze the application effect of amoxicillin clavulanate potassium combined with third-generation cephalosporin antibiotics in children with neonatal pneumonia and its impact on the intestinal microbiota．Methods From February 2021 to November 2022,100 newborns with pneumonia who received relevant treatment in the Department of Neonatology at the First People’s Hospital of Shangqiu City were randomly divided into a study group（n=50）and a reference group（n=50）using a simple randomization method．Routine treatment was provided for neonatal pneumonia in the reference group,and on this basis,a combination treatment of amoxicillin,clavulanate potassium,and third-generation cephalosporin antibiotics was applied on the study group patients．After treatment,the serum factor levels,intestinal colony status,clinical efficacy,and incidence of adverse reactions were compared between the two groups of children．Results Before treatment,there were no statistically significant differences in serum factor levels and intestinal microbiota between the two groups of children（P>0.05）．After treatment,the levels of procalcitonin（PCT）,C-reactive protein（CRP）,white blood cell count（WBC）,Enterococcus,Enterobacter,Bifidobacterium,and Lactobacillus in the two groups of children improved（P<0.05）,with the levels of PCT,CRP,WBC,the number of Enterococcus,Bifidobacterium,and Lactobacillus in the study group was lower than that in the reference group,while the number of Enterobacter in the study group was higher．There was no statistically significant difference（P>0.05）in the clinical response rate between the study group（94.00%）and the reference group（86.00%）．There was no statistically significant difference in the incidence of adverse reactions between the two groups of children（P>0.05）,but the incidence of diarrhea in the study group was higher than that in the reference group（P<0.05）．Conclusions The clinical efficacy of amoxicillin clavulanate potassium alone and amoxicillin clavulanate potassium+third-generation cephalosporin antibiotics（ceftazidime）in the treatment of newborns with pneumonia is comparable．Although the combination therapy can significantly reduce the number of bacteria in the body of children and improve serum factor levels,it is more prone to complications of diarrhea．In order to reduce drug resistance,separate medication should be appropriately used．
目的 探讨清热化痰宣肺汤治疗痰热壅肺型重症肺炎的临床效果。方法 选择2022年3月—2023年6月天津市中西医结合医院收治的158例痰热壅肺型重症肺炎患者进行探讨,采用随机分组法分为研究组和对照组,每组各79例,对照组接受常规对症处理联合抗生素治疗,研究组在对照组基础上给予清热化痰宣肺汤,两组均治疗2周,比较疗效、中医证候积分、肺功能、血气分析结果以及不良反应发生情况。结果 研究组总有效率为94.94%,高于对照组的84.81（P=0.035）;研究组治疗后发热、痰壅以及气促评分分别为（1.12±0.33）分、（1.02±0.28）分及（1.16±0.30）分;对照组治疗后发热、痰壅以及气促评分分别为（1.45±0.36）分、（2.11±0.42）分及（2.06±0.39）分,研究组和对照组各项评分均较治疗前降低（均P<0.05）,研究组低于对照组（P均<0.05）;治疗后研究组PEF、FEV1、FVC以及MVV分别为（3.48±0.53）L/s、（2.95±0.52）L、（2.98±0.58）L、（88.15±5.25）L/min,治疗后对照组的PEF、FEV1、FVC以及MVV分别为（4.22±0.53）L/s、（2.41±0.47）L、（2.98±0.58）L、（88.15±5.25）L/min,两组均较治疗前升高（均P<0.05）,且研究组高于对照组（均P<0.05）; 治疗后研究组和对照组PaO2分别为（9.77±1.12）kPa、（9.33±1.09）kPa,均较治疗前升高（均P<0.05）,研究组高于对照组（P=0.013）,治疗后研究组和对照组的PaCO2分别为（4.22±0.14）kPa、（5.11±0.16）kPa,均较治疗前下降（均P<0.05）,研究组低于对照组（P<0.001）;研究组出现3例恶心不良反应,对照组未见不良反应发生,组间无显著差异（P>0.05）。结论 清热化痰宣肺汤治疗痰热壅肺型重症肺炎效果理想,可明显改善肺功能及血气指标,且具有较高安全性。
目的 分析厄贝沙坦+美托洛尔治疗慢性充血性心力衰竭(congestive heart failure,CHF)的临床效果及对患者心功能影响。方法 选取本院2018年12月—2020年12月住院治疗的200例慢性CHF患者,根据不同的治疗方法分组,参照组100例患者采用厄贝沙坦治疗,治疗组100例患者采用厄贝沙坦+美托洛尔治疗,比较2组临床疗效、心功能指标、血清炎性因子、血清N端脑利钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、同型半胱氨酸(homocysteine,Hcy)水平、不良反应发生率。结果 治疗组临床总有效率(97.00%)高于参照组(87.00%),治疗组治疗后左室射血分数(left ventricular ejection fraction,LVEF)高于参照组,治疗组治疗后左室舒张末期内径(left ventricular end diastolic diameter,LVEDd)、左室收缩末期内径(left ventricular end systolic diameter,LVESd)、血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、超敏C反应蛋白(hypersensitivity C-reactive protein,hs-CRP)、白细胞介素-6(interleukin-6,IL-6)、NT-proBNP、Hcy水平均低于参照组,差异均具有统计学意义(P＜0.05)。治疗组不良反应发生率(4.00%)与参照组(5.00%)比较,P>0.05。结论 厄贝沙坦+美托洛尔可有效改善慢性CHF患者心功能,减轻炎症反应,抑制NT-proBNP、Hcy释放,且不良反应较少。
Objective To analyze the clinical effect of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure (CHF) and its influence on cardiac function. Methods A total of 200 patients with chronic CHF in our hospital from December 2018 to December 2020 were selected and divided into two groups according to different treatment methods. One handred patients in the control group were treated with irbesartan, and 100 patients in the treatment group were treated with irbesartan + metoprolol. The clinical efficacy, cardiac function indexes, serum inflammatory factors, serum NT-proBNP, Hcy levels and adverse reactions of the two groups were compared. Results The total effective rate of the treatment group (97.00%) was higher than that of the control group (87.00%), LVEF of the treatment group was higher than that of the control group, LVEDd, LVESd, serum TNF-α, hs-CRP, IL-6, NT-proBNP, Hcy levels of the treatment group were lower than those of the control group, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the treatment group (4.00%) was higher than that in the control group (5.00%),P>0.05. Conclusion Irbesartan + metoprolol could effectively improve cardiac function, reduce inflammatory reaction, inhibit the release of NT-proBNP and Hcy in patients with chronic CHF, with less adverse reactions.
目的 探讨围绝经期功能失调性子宫出血患者应用宫腔镜电切术联合炔诺酮治疗对临床效果的影响。方法 选取2017年1月—2020年9月在我院治疗的87例围绝经期功能失调性子宫出血患者,按照随机数字表法分成观察组(n=44)与对照组(n=43),观察组采用宫腔镜电切术联合炔诺酮治疗,对照组仅采用宫腔镜电切术治疗,比较2组临床疗效、手术情况、住院时间、不良反应发生率,分析治疗前后子宫形态、血红蛋白含量变化。结果 观察组治疗总有效率为100.00%,对照组为86.05%,观察组高于对照组(P<0.05);2组手术时间、术中出血量、膨宫液用量、住院时间比较无差异(P>0.05);2组治疗后子宫内膜厚度增加(P<0.05),血红蛋白水平下降(P<0.05),观察组子宫内膜厚度大于对照组(P<0.05),血红蛋白水平较对照组更低(P<0.05);观察组不良反应发生率为9.09%,对照组为27.91%,观察组低于对照组(P<0.05)。结论 宫腔镜电切术联合炔诺酮应用于围绝经期功能失调性子宫出血患者治疗中能够促进子宫状况改善,提高临床疗效,且安全性较高,值得临床推广。
